- Benzinga•7 hours ago
HC Wainwright has started coverage of vTv Therapeutics Inc (NASDAQ: VTVT ) with a Buy rating and $13 price target on the potential success of its three late-stage drugs, especially the two diabetic compounds. ...
- Reuters•16 hours ago
French drugmaker Sanofi and its U.S. partner Regeneron Pharmaceuticals could win U.S. approval for their keenly awaited new eczema drug dupilumab, seen by analysts as a potential $3 billion-a-year seller, by next March. Sanofi badly needs new products to make up for flagging sales in its diabetes business, where its top-seller Lantus faces growing competition. The two companies said on Monday that the U.S. Food and Drug Administration had accepted dupilumab for priority review for treating atopic dermatitis (AD), a skin inflammation also known as atopic eczema, and set a target decision date of March 29.
AstraZeneca PLC (AZN.L)
LSE - LSE Delayed Price. Currency in GBp
|Bid||5,091.00 x 6100|
|Ask||5,200.00 x 13000|
|Day's Range||5,098.82 - 5,184.57|
|52wk Range||3,680.00 - 5,505.00|
|1y Target Est||N/A|
|P/E Ratio (ttm)||29.14|
|Avg Vol (3m)||2,741,863|
|Dividend & Yield||N/A (N/A)|